IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

86 Drug Developers Raised $17bn, Generated 86% Average Return

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Pixelated acronym IPO made from cubes, mosaic pattern
Out of 86 companies that went public last year, 67 were trading above their IPO values as of 27 January • Source: Shutterstock

The stars aligned in 2020 for a record-breaking year of 86 biopharmaceutical companies launching initial public offerings in the US, which raised $17.04bn and generated an 86% average return as of 27 January. There was an abundance of innovative companies in need of capital to grow as well as a lot of investment capital looking to back novel technologies. The COVID-19 pandemic served as an additional driver by boosting investor interest in drug developers and enabling a more efficient IPO process.

After a brief period from mid-March to mid-April when uncertainty around the novel coronavirus shut down the global economy, the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.